Belldegrun Arie has filed 16 insider transactions across 3 companies since March 2023.
Most recent transaction: a grant/award of 263033 shares of Allogene Therapeutics, Inc. ($ALLO) on February 02, 2026.
Activity breakdown: 1 open-market purchase and 0 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 2, 2026 | Allogene Therapeutics, Inc. | $ALLO | Belldegrun Arie | Director | A | Restricted Stock Unit | 263033 | $0.00 | 263,033.0000 | 224,730,144 | 9999.99% | 0.12% |
| Feb. 2, 2026 | Allogene Therapeutics, Inc. | $ALLO | Belldegrun Arie | Director | A | Stock Option (Right to buy) | 929913 | $0.00 | 929,913.0000 | 224,730,144 | 9999.99% | 0.41% |
| Aug. 26, 2025 | UroGen Pharma Ltd. | $URGN | Belldegrun Arie | Director | A | Stock Option (right ot buy) | 20000 | $0.00 | 20,000.0000 | 47,030,820 | 9999.99% | 0.04% |
| Jan. 24, 2025 | Allogene Therapeutics, Inc. | $ALLO | Belldegrun Arie | Director | A | Common Stock | 369957 | $0.00 | 11,009,103.0000 | 0 | 3.48% | 0.00% |
| Jan. 24, 2025 | Allogene Therapeutics, Inc. | $ALLO | Belldegrun Arie | Director | A | Stock Option (Right to buy) | 1307927 | $0.00 | 1,307,927.0000 | 0 | 9999.99% | 0.00% |
| Aug. 6, 2024 | UroGen Pharma Ltd. | $URGN | Belldegrun Arie | Director | A | Stock Option (right ot buy) | 10000 | $0.00 | 10,000.0000 | 40,501,315 | 9999.99% | 0.02% |
| June 12, 2024 | Ginkgo Bioworks Holdings, Inc. | $DNA | Belldegrun Arie | Director | M | Class A Common Stock | 105263 | $0.00 | 694,925.0000 | 50,032,873 | 17.85% | 0.21% |
| June 12, 2024 | Ginkgo Bioworks Holdings, Inc. | $DNA | Belldegrun Arie | Director | M | Restricted Stock Units | 105263 | $0.00 | 0.0000 | 50,032,873 | 100.00% | 0.21% |
| June 13, 2024 | Ginkgo Bioworks Holdings, Inc. | $DNA | Belldegrun Arie | Director | A | Restricted Stock Units | 432900 | $0.00 | 432,900.0000 | 50,032,873 | 9999.99% | 0.87% |
| June 13, 2024 | Ginkgo Bioworks Holdings, Inc. | $DNA | Belldegrun Arie | Director | A | Stock Option | 571428 | $0.00 | 571,428.0000 | 50,032,873 | 9999.99% | 1.14% |
| May 16, 2024 | Allogene Therapeutics, Inc. | $ALLO | Belldegrun Arie | Director | P | Common Stock | 1724137 | $2.90 | 10,099,279.0000 | 0 | 20.59% | 0.00% |
| May 16, 2024 | Allogene Therapeutics, Inc. | $ALLO | Belldegrun Arie | Director | A | Common Stock | 344828 | $2.90 | 8,915,009.0000 | 0 | 4.02% | 0.00% |
| Jan. 25, 2024 | Allogene Therapeutics, Inc. | $ALLO | Belldegrun Arie | Not found | A | Stock Option (Right to buy) | 749398 | $0.00 | 749,398.0000 | 0 | 9999.99% | 0.00% |
| Jan. 25, 2024 | Allogene Therapeutics, Inc. | $ALLO | Belldegrun Arie | Not found | A | Common Stock | 211973 | $0.00 | 8,570,181.0000 | 0 | 2.54% | 0.00% |
| March 22, 2023 | Allogene Therapeutics, Inc. | $ALLO | Belldegrun Arie | Not found | A | Common Stock | 1282976 | $0.00 | 8,358,208.0000 | 0 | 18.13% | 0.00% |
| March 22, 2023 | Allogene Therapeutics, Inc. | $ALLO | Belldegrun Arie | Not found | A | Stock Option (Right to Buy) | 994800 | $0.00 | 994,800.0000 | 0 | 9999.99% | 0.00% |